Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethlamide, in a mouse model of amyotrophic lateral sclerosis

Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY 10065, USA.
Free Radical Biology and Medicine (Impact Factor: 5.74). 03/2011; 51(1):88-96. DOI: 10.1016/j.freeradbiomed.2011.03.027
Source: PubMed


Oxidative damage, neuroinflammation, and mitochondrial dysfunction contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS), and these pathologic processes are tightly regulated by the Nrf2/ARE (NF-E2-related factor 2/antioxidant response element) signaling program. Therefore, modulation of the Nrf2/ARE pathway is an attractive therapeutic target for neurodegenerative diseases such as ALS. We examined two triterpenoids, CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) ethylamide and CDDO trifluoroethylamide (CDDO-TFEA), that potently activate Nrf2/ARE in a cell culture model of ALS and in the G93A SOD1 mouse model of ALS. Treatment of NSC-34 cells stably expressing mutant G93A SOD1 with CDDO-TFEA upregulated Nrf2 expression and resulted in translocation of Nrf2 into the nucleus. Western blot analysis showed an increase in the expression of Nrf2/ARE-regulated proteins. When treatment started at a "presymptomatic age" of 30days, both of these compounds significantly attenuated weight loss, enhanced motor performance, and extended the survival of G93A SOD1 mice. Treatment started at a "symptomatic age," as assessed by impaired motor performance, was neuroprotective and slowed disease progression. These findings provide further evidence that compounds that activate the Nrf2/ARE signaling pathway may be useful in the treatment of ALS.

29 Reads
  • Source
    • "Encouraging studies have been performed also in ALS models. The Nrf2/ARE activators CDDO ethylamide and CDDO 3-fluoroethylamide significantly attenuated weight loss, enhanced motor performance, and extended the survival of SOD1G93A mice [54], although these findings have not been confirmed in a subsequent study in which knocking out Nrf2 gene in SOD1G93A mice had only a modest impact on the course of disease [55]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oxidative stress involvement has been strongly hypothesized among the possible pathogenic mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis (ALS). The intracellular redox balance is finely modulated by numerous complex mechanisms critical for cellular functions, among which the nuclear factor erythroid-derived 2-like 2 (NFE2L2/Nrf2) pathways. We genotyped, in a cohort of ALS patients (n = 145) and healthy controls (n = 168), three SNPs in Nrf2 gene promoter: −653 A/G, −651 G/A, and −617 C/A and evaluated, in a subset (n = 73) of patients, advanced oxidation protein products (AOPP), iron-reducing ability of plasma (FRAP), and plasma thiols (-SH) as oxidative damage peripheral biomarkers. Nrf2 polymorphisms were not different among patients and controls. Increased levels of AOPP (P < 0.05) and decreased levels of FRAP (P < 0.001) have been observed in ALS patients compared with controls, but no difference in -SH values was found. Furthermore, no association was found between biochemical markers of redox balance and Nrf2 polymorphisms. These data confirm an altered redox balance in ALS and indicate that, while being abnormally modified compared to controls, the oxidative stress biomarkers assessed in this study are independent from the −653 A/G, −651 G/A, and −617 C/A Nrf2 SNPs in ALS patients.
    Oxidative Medicine and Cellular Longevity 02/2014; 2014(5):432626. DOI:10.1155/2014/432626 · 3.36 Impact Factor
  • Source
    • "Restoring balanced levels of redox - sensitive transcription fac - tors and enzymes through Nrf2 induction has been demonstrated in a number of mouse models of neurodegenerative disease ( Jakel et al . , 2007 ; Kanninen et al . , 2009 ; Neymotin et al . , 2011 ; Pareek et al . , 2011 ) but perhaps confusing a downstream antioxidant ac - tivity with the upstream activation of redox controls , as shown here . The strategy of a combination of energy precursor and redox stimulators to induce multiple targets including NADH , NADPH , signaling pathways , metabolism , and so forth shown here to be "
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether glutathione (GSH) loss or increased reactive oxygen species (ROS) are more important to neuron loss, aging, and Alzheimer's disease (AD), we stressed or boosted GSH levels in neurons isolated from aging 3xTg-AD neurons compared with those from age-matched nontransgenic (non-Tg) neurons. Here, using titrating with buthionine sulfoximine, an inhibitor of γ-glutamyl cysteine synthetase (GCL), we observed that GSH depletion increased neuronal death of 3xTg-AD cultured neurons at increasing rates across the age span, whereas non-Tg neurons were resistant to GSH depletion until old age. Remarkably, the rate of neuron loss with ROS did not increase in old age and was the same for both genotypes, which indicates that cognitive deficits in the AD model were not caused by ROS. Therefore, we targeted for neuroprotection activation of the redox sensitive transcription factor, nuclear erythroid-related factor 2 (Nrf2) by 18 alpha glycyrrhetinic acid to stimulate GSH synthesis through GCL. This balanced stimulation of a number of redox enzymes restored the lower levels of Nrf2 and GCL seen in 3xTg-AD neurons compared with those of non-Tg neurons and promoted translocation of Nrf2 to the nucleus. By combining the Nrf2 activator together with the NADH precursor, nicotinamide, we increased neuron survival against amyloid beta stress in an additive manner. These stress tests and neuroprotective treatments suggest that the redox environment is more important for neuron survival than ROS. The dual neuroprotective treatment with nicotinamide and an Nrf2 inducer indicates that these age-related and AD-related changes are reversible.
    Neurobiology of aging 08/2013; 35(1). DOI:10.1016/j.neurobiolaging.2013.06.023 · 5.01 Impact Factor
  • Source
    • "The triterpenoid family consists in three chemically related members: 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid ethylamide (CDDO-EA), CDDO trifluoroethylamide (CDDO-TFEA), and CDDO methylamide (CDDO-MA). Triterpenoids have shown a paramount potency in Nrf2 induction, the ability to attenuate dopaminergic neurodegeneration in MPTP mouse model of PD [117], and increase the life span in ALS mouse models [118]. Another interesting small chemical activator of Nrf2/ARE pathway is CPN-9 which selectively suppresses cell death triggered by OS in a cell-type-independent manner. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurodegenerative diseases share diverse pathological features and among these oxidative stress (OS) plays a leading role. Impaired activity and reduced expression of antioxidant proteins have been reported as common events in several aging-associated disorders. In this review paper, we first provide an overview of the involvement of reactive oxygen species- (ROS-) induced oxidative damage in Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). Subsequently, we focus on DJ-1 and SOD1 proteins, which are involved in PD and ALS and also exert a prominent role in the interaction between redox homeostasis and neurodegeneration. Interestingly, recent studies demonstrated that DJ-1 and SOD1 are both tightly connected with Nrf2 protein, a transcriptional factor and master regulator of the expression of many antioxidant/detoxification genes. Nrf2 is emerging as a key neuroprotective protein in neurodegenerative diseases, since it helps neuronal cells to cope with toxic insults and OS. We herein summarize the recent literature providing a detailed picture of the promising therapeutic efficacy of Nrf2 natural and synthetic inducers as disease-modifying molecules for the treatment of neurodegenerative diseases.
    Oxidative Medicine and Cellular Longevity 07/2013; 2013:836760. DOI:10.1155/2013/836760 · 3.36 Impact Factor
Show more